VOYAGER THERAPEUTICS
Voyager Therapeutics is a gene therapy company developing treatments for fatal and debilitating diseases of the central nervous system (CNS). It is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia.
VOYAGER THERAPEUTICS
Industry:
Biotechnology Genetics Health Care Life Science
Founded:
2014-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.voyagertherapeutics.com
Total Employee:
101+
Status:
Active
Contact:
857-259-5340
Total Funding:
374 M USD
Technology used in webpage:
IPv6 COVID-19 DigiCert SSL Akamai Hosted RapidSSL About Cookies
Similar Organizations
ArcherDX
ArcherDX is a biotechnology firm specializing in cancer research.
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Tessera Therapeutics
Tessera Therapeutics is a biotechnology company that focuses on a new category of genetic medicines.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Board_member
2023-01-01
Board_member
Board_member
2020-09-01
Current Employees Featured
Mark Kay Scientific Founder & SAB member @ Voyager Therapeutics
Scientific Founder & SAB member
2014-01-01
Steven Paul Senior Advisor, Co-founder & Board Member @ Voyager Therapeutics
Senior Advisor, Co-founder & Board Member
2018-08-01
Guangping Gao Co-Founder @ Voyager Therapeutics
Co-Founder
Krystof Bankiewicz Co-Founder @ Voyager Therapeutics
Co-Founder
Phillip D. Zamore Co-Founder @ Voyager Therapeutics
Co-Founder
Steven Paul Co-Founder @ Voyager Therapeutics
Co-Founder
2014-01-01
Alfred W. Sandrock Jr. CEO @ Voyager Therapeutics
CEO
2022-03-01
Todd Carter Chief Scientific Officer (CSO) @ Voyager Therapeutics
Chief Scientific Officer (CSO)
2022-09-01
Dinah Sah SAB @ Voyager Therapeutics
SAB
2019-06-01
Robert W. Hesslein Senior Vice President / General Counsel @ Voyager Therapeutics
Senior Vice President / General Counsel
2019-04-01
Founder
Stock Details
Investors List
Neurocrine Biosciences
Neurocrine Biosciences investment in Post-IPO Equity - Voyager Therapeutics
Fidelity
Fidelity investment in Series B - Voyager Therapeutics
Casdin Capital
Casdin Capital investment in Series B - Voyager Therapeutics
Partner Fund Management
Partner Fund Management investment in Series B - Voyager Therapeutics
Wellington Management
Wellington Management investment in Series B - Voyager Therapeutics
Brookside Capital
Brookside Capital investment in Series B - Voyager Therapeutics
Deerfield
Deerfield investment in Series B - Voyager Therapeutics
Genzyme
Genzyme investment in Corporate Round - Voyager Therapeutics
Third Rock Ventures
Third Rock Ventures investment in Series A - Voyager Therapeutics
Key Employee Changes
Official Site Inspections
http://www.voyagertherapeutics.com Semrush global rank: 3.3 M Semrush visits lastest month: 4.27 K
- Host name: 57.252.154.104.bc.googleusercontent.com
- IP address: 104.154.252.57
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Voyager Therapeutics"
About – Leadership - Voyager Therapeutics
He currently serves on the board of directors of the World Federation of Hemophilia and as the organization’s Vice President, Medical. Pierce received B.A. in biology, an M.D. and a Ph.D. in …See details»
Voyager Therapeutics - Defining Neurogenetic Medicine
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases.See details»
About – Overview - Voyager Therapeutics
INVESTORS CAREERS Overview Job Openings Our Community Core Values Benefits Disclosures About Breaking through barriers. Advancing transformative treatments.See details»
Voyager Therapeutics, Inc. - LinkedIn
For more information, visit www.voyagertherapeutics.com. Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.See details»
Voyager Therapeutics - Crunchbase Company Profile & Funding
Voyager Therapeutics reported a 58% gain for investors who invested three years ago. The company also collected a milestone payment as part of its ongoing collaboration with Novartis. …See details»
Investors | Voyager Therapeutics Inc.
Feb 21, 2025 Some of our programs are wholly owned, and some are advancing with partners including Alexion; AstraZeneca Rare Diseases; Novartis Pharma AG; and Neurocrine …See details»
ir.voyagertherapeutics.com
Ir.voyagertherapeutics.comSee details»
Voyager Therapeutics (BMV:VYGR) Company Profile & Description
6 days ago Company profile for Voyager Therapeutics, Inc. (BMV:VYGR) with a description, list of executives, contact details and other key facts.See details»
Voyager Therapeutics Inc Company Profile - Overview
Voyager Therapeutics Inc (Voyager) is a biotechnology company that focuses on the development of genetic medicines to treat neurological diseases. The company's pipeline products include …See details»
Voyager Therapeutics
May 20, 2025 Voyager was founded in 2014 by members of the neuroscience community with experience in gene therapy and neurologic diseases.The Company has since built an …See details»
Voyager Therapeutics, Inc. - MassBio
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been …See details»
Voyager Reports First Quarter 2025 Financial and Operating Results
LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological …See details»
Voyager Therapeutics Announces Strategic Shift and Leadership ...
May 19, 2021 Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing …See details»
Press Releases - Voyager Therapeutics Inc.
Stay updated with the latest press releases and news from Voyager Therapeutics, a biopharmaceutical company focused on developing treatments for neurological diseases.See details»
Voyager Therapeutics Announces Pfizer License of Next …
Oct 4, 2022 Proprietary capsids born from the Company’s TRACER discovery platform are powering a rich early-stage pipeline of programs and may elevate the field to overcome the …See details»
Careers – Culture - Voyager Therapeutics
Diversity at Voyager Diversity is the acknowledgement of the experiences that make us unique as well as the appreciation for our entire person. Diversity is achieved through mutual respect, …See details»
Voyager Therapeutics - 2025 Company Profile - Tracxn
6 days ago Voyager Therapeutics - Gene Therapy to treat CNS diseases such as Parkinson’s disease, ALS.. Public Company. Raised a total funding of $105M over 5 rounds from 9 investors.See details»
Company: Voyager Therapeutics - CRISPR Medicine
Voyager Therapeutics is a pre-clinical-stage biotech whose main technology TRACER® allows for screening and identification of new adeno-associated virus (AAV) serotypes with better …See details»
Voyager Therapeutics Presents New Data on Tau Silencing Gene
Apr 28, 2025 Voyager Therapeutics presents data on tau silencing therapy VY1706 and anti-amyloid therapy at ASGCT 2025. Quiver AI Summary Voyager Therapeutics, Inc. has …See details»
Voyager Selects Tau Silencing Gene Therapy Development …
- Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in 2026 - - VY1706 is the fifth neuro gene therapy development …See details»